Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

著者： Lynn Marie Morski MD JD
無料で聴く

  • サマリー

  • Curious about the possible therapeutic benefits of psychedelic medicines? The Psychedelic Medicine Podcast with Dr. Lynn Marie Morski has you covered with the latest in scientific research, medical practices, and legal developments involving these substances and their incredible therapeutic potential. Covering the full range of psychedelic therapies, including psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and more, this podcast serves as an auditory encyclopedia of information for anyone interested in learning about the safe, therapeutic uses of these medicines.
    All podcast episodes and show notes are copyright Lynn Marie Morski, 2023.
    続きを読む 一部表示

あらすじ・解説

Curious about the possible therapeutic benefits of psychedelic medicines? The Psychedelic Medicine Podcast with Dr. Lynn Marie Morski has you covered with the latest in scientific research, medical practices, and legal developments involving these substances and their incredible therapeutic potential. Covering the full range of psychedelic therapies, including psilocybin, MDMA, ketamine, LSD, ayahuasca, ibogaine, and more, this podcast serves as an auditory encyclopedia of information for anyone interested in learning about the safe, therapeutic uses of these medicines.
All podcast episodes and show notes are copyright Lynn Marie Morski, 2023.
心理学 衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • Psilocybin for Obsessive-Compulsive Disorder (OCD) with Sorcha O'Connor, PhD(c)

    Psilocybin for Obsessive-Compulsive Disorder (OCD) with Sorcha O'Connor, PhD(c)
    2025/01/09

    In this episode, Sorcha O'Connor, PhD(c) joins to discuss the research into the use of psilocybin to address obsessive-compulsive disorder (OCD). Sorcha is completing her neuroscience PhD at Imperial College London, specialising in mental health research. She led PsilOCD, a pioneering study investigating low-dose psilocybin as a treatment for both the clinical symptoms and cognitive features of OCD.

    In this conversation, Sorcha introduces obsessive-compulsive disorder and discusses the ways medical professionals are currently thinking about this and other related conditions. She mentions that current therapies for OCD often only minimally improve symptoms, emphasizing the need for better treatment options. This led to studies exploring psilocybin as a treatment for OCD - and Sorcha emphasizes that the early trials have shown positive results, often with significant decreases in OCD symptoms. In conclusion, Sorcha discusses the protocol for the PsilOCD study at Imperial College London, with results from this study soon to be published.

    In this episode you'll hear:

    • The features of obsessive-compulsive disorder (OCD)
    • The history and development of treatments for OCD
    • The theory behind the hypothesis that psilocybin may be effective for OCD
    • Trials exploring the efficacy of psychedelic treatments for OCD
    • Why psilocybin has come to the fore more than LSD or ketamine for prospective OCD studies
    • How patients are evaluated for OCD

    Quotes:

    “[OCD] is this complex behavioral pattern and certain medications moderately help and nothing seems to be highly effective yet and that definitely points to the need for novel pharmacotherapy.” [12:46]

    “[By utilizing lower doses of psilocybin], people who maybe fixate on their health and on their mental health and sensations and things can benefit from psilocybin without having to overcome that barrier.” [18:25]

    Links:

    Sorcha on LinkedIn

    PsilOCD Study details on the Imperial College London website

    Dr. Michael J. Greenberg’s website

    Psychedelic Medicine Association

    Porangui
    続きを読む 一部表示
    36 分
  • Ending Pill Shaming: How Psychedelics and Pharmaceuticals Can Both Support Healing with Erica Zelfand, ND

    Ending Pill Shaming: How Psychedelics and Pharmaceuticals Can Both Support Healing with Erica Zelfand, ND
    2024/12/18
    In this episode, Erica Zelfand, ND joins to discuss the important topic of pill shaming in psychedelic communities and how psychedelic medicine and traditional pharmaceuticals can both support healing. Dr. Erica Zelfand specializes in integrative mental health, bridging the gaps between conventional and alternative medicine. In addition to seeing patients in private practice, she also teaches facilitation internationally and leads retreats through Right to Heal. In this conversation, Dr. Zelfand tackles the issue of pill shaming in psychedelic communities, showing why this rhetoric falls short and ultimately harms patients. She discusses complementary roles for psychedelic and traditional pharmaceutical medicines, suggesting that a medicine like ketamine may be particularly effective in contexts of acute intervention, whereas an SSRI antidepressant may be most effective for maintenance. Dr. Zelfand notes, however, that drug-drug interactions can be a significant concern and stresses the need for medical expertise and supervision in the context of concomitant usage of pharmaceuticals and psychedelics. In closing, she emphasizes that what is ultimately important is that patients are able to progress in healing, and any tools that are able to safely and effectively support this goal have an important role to play and should not be denigrated. In this episode you'll hear: The pill shaming rhetoric in psychedelic and cannabis communitiesPharmaceutical contraindications to psychedelic therapy and the necessity of medical supervision for tapering off such medicationsWhy comparing traditional antidepressant pharmaceuticals to psychedelic medicines is often an apples to oranges comparisonThe issues with “no pain, no gain” rhetoric in healingPsychiatric support for processing repressed memories uncovered during psychedelic journeys Quotes: “When I went into medicine, I actually specifically went into integrative medicine, functional medicine, because I didn’t like that patients were being in this position of having to choose: the conventional route or the alternative medicine route. Both routes have their merits and both routes have their shortcomings and I felt like we all deserve to be able to access both and have it be an integrated model.” [3:06] “The only form of ketamine that is FDA approved for depression—which is Spravato—is only approved in the context in which the person is also taking an oral antidepressant.” [20:48] “We have data showing that if you feel really really freaked out and anxious during your [psychedelic] trip, your outcomes aren’t necessarily as good. And the biggest predictor of having a positive experience is actually feeling awe. You don’t have to do the ego death thing, but if you can feel awe, if you can feel inspiration during a trip, your outcomes are better. And there’s even data showing that individuals who are on an SSRI and then trip—they may actually have better outcomes than people who don’t take medication.” [24:12] “I think part of this trepidation is we don’t want to harm anybody through a dangerous, or potentially lethal, drug-drug interaction. That’s one thing. It’s another thing to be like ‘yeah but if you’re using these [pharmaceutical] drugs you’re doing it wrong and you’re not healing right.’ And I think the one often is used as a camouflage for the other—and they’re two separate things.” [38:59] Links: Dr. Zelfan’s website Dr. Zelfand on Instagram Dr. Zelfand on Twitter Dr. Zelfan on LinkedIn Right to Heal website Psychedelic pill-shaming article by Jules Evans and Shayam Suseelan Previous episode: Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA Previous episode: Warning Signs When Selecting a Psychedelic Facilitator with Juliana Mulligan Previous episode: How to Choose a Psychedelic Facilitator or Retreat Center with Joël Brierre Psychedelic Medicine Association Porangui
    続きを読む 一部表示
    46 分
  • Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA, LPC

    Integrating Challenging Psychedelic Experiences with Keith Kurlander, MA, LPC
    2024/12/04

    In this episode of the Psychedelic Medicine Podcast, Keith Kurlander, MA, LPC, joins to discuss the important topic of integration practices for challenging psychedelic experiences. Keith is the Co-Founder of the Integrative Psychiatry Institute, the largest professional education company specializing in integrative mental health and psychedelic therapy.

    In this conversation, Keith begins by exploring the different types of challenging psychedelic experiences and various lingering effects one may experience following a difficult psychedelic journey. He discusses these from a trauma-informed perspective, explaining how a traumatized nervous system can lead to dissociation on the other side of an intense ego-disrupting experience. Keith also shares practices and insights from internal family systems (IFS) for integrating challenging psychedelic experiences. In closing, he emphasizes that psychedelics are not lazer-targeted therapies, so they do carry inherent risks, but through effective integration practices, patients can make healthy meaning out of even negative experiences.

    In this episode you'll hear:

    • Lingering issues with ego fragmentation and connections to the dissociative disorder spectrum
    • Persisting psychotic disorders following psychedelic experiences
    • The difference between CPTSD and PTSD
    • Uncovering repressed traumatic memories during psychedelic journeys
    • Trauma stemming from difficult psychedelic experiences
    • Challenging spiritual experiences

    Quotes:

    “The concept of pendulation [is] that we can be more flexible to ease our way into these overwhelming states. So once we are totally overwhelmed, we have to work our way back out gracefully, but as we are doing that, you get a gem as you are coming back… you learn something as you are coming out of that state.” [18:02]

    “If people have a psychotic disorder that emerged after their psychedelic use, you need a psychiatrist at that point… If it’s really a psychotic emergence, whether a previous psychotic disorder got triggered or whatever, you need a psychiatrist to work with you on that.” [20:07]

    “I believe all these mental health conditions have a trauma process underneath them. I don’t know how you isolate a trauma process from a mental health condition” [25:30]

    “It’s about working with a person’s meaning-making structure: is the meaning they’re making creating more psychological flexibility or less psychological flexibility? That’s a really important question to hold as a therapist because people will make all kinds of meaning up from these experiences but if they’re creating meaning that’s creating more rigid structures of how they see the world, then they get disappointed more often.” [34:21]

    Links:

    Psychiatry Institute website

    Keith’s website

    Keith on Instagram

    Higher Practice podcast

    Previous episode: The Challenging Psychedelic Experiences Project with Jules Evans

    Psychedelic Medicine Association

    Porangui
    続きを読む 一部表示
    40 分

Psychedelic Medicine Podcast with Dr. Lynn Marie Morskiに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。